Novo Nordisk

Global obesity drugs sales could top $44bn in 2030, says Bloomberg Intelligence
Global obesity drugs sales could top $44bn in 2030, says Bloomberg Intelligence
Biopharma Reporter
obesity
weight loss
Novo Nordisk
Eli Lilly
Pfizer
Amgen
Flag link:
This Could Be Novo Nordisk's Next Big Weight-Loss Product
This Could Be Novo Nordisk's Next Big Weight-Loss Product
Motley Fool
Novo Nordisk
weight loss
Wegovy
oral Wegovy
Flag link:
Pfizer's hemophilia drug hits in phase 3, giving it a chance to leapfrog Novo Nordisk
Pfizer's hemophilia drug hits in phase 3, giving it a chance to leapfrog Novo Nordisk
Fierce Biotech
Pfizer
Novo Nordisk
clinical trials
hemophilia
marstacimab
Flag link:
Noom to offer prescriptions for weight-loss drugs
Noom to offer prescriptions for weight-loss drugs
Yahoo Finance
Noom
weightloss
Novo Nordisk
Eli Lilly
Wegovy
Ozempic
Mounjaro
Flag link:
Novo marks a century in business with corporate campaign launch
Novo marks a century in business with corporate campaign launch
Medical Marketing and Media
Novo Nordisk
corporate branding
Flag link:
Novo makes a gene editing move
Novo makes a gene editing move
EP Vantage
Novo Nordisk
gene editing
Life Edit Therapeutics
Flag link:
Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss
Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss
Investors Business Daily
Pfizer
Novo Nordisk
weight loss
Ozempic
danuglipron
clinical trials
Flag link:
Novo Nordisk’s trial of oral semaglutide meets primary endpoint
Novo Nordisk’s trial of oral semaglutide meets primary endpoint
Clinical Trials Arena
Novo Nordisk
semaglutide
oral semaglutide
clinical trials
weight loss
Flag link:
Novo Nordisk pauses Wegovy marketing projects to dampen demand
Novo Nordisk pauses Wegovy marketing projects to dampen demand
Fierce Pharma
Novo Nordisk
Wegovy
weight loss
DTC advertising
Flag link:
What you need to know about pharma, PBM execs testifying on insulin prices
What you need to know about pharma, PBM execs testifying on insulin prices
Medical Marketing and Media
PBMs
insulin
diabetes
drug pricing
Sanofi
Novo Nordisk
Eli Lilly
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:
‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs
‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs
Stat
side effects
Ozempic
Wegovy
Mounjaro
Novo Nordisk
Eli Lilly
obesity
Flag link:
Amid high demand, Novo Nordisk temporarily throttles US supply of low-dose Wegovy
Amid high demand, Novo Nordisk temporarily throttles US supply of low-dose Wegovy
Fierce Pharma
Novo Nordisk
Wegovy
obesity
Flag link:
Novo Nordisk Q1 Earnings In Line, Sales Miss, View Up
Novo Nordisk Q1 Earnings In Line, Sales Miss, View Up
Yahoo/Zacks.com
Novo Nordisk
earnings
Flag link:
In heavyweight obesity fight, Eli Lilly launches Mounjaro head-to-head trial against Novo Nordisk's Wegovy
In heavyweight obesity fight, Eli Lilly launches Mounjaro head-to-head trial against Novo Nordisk's Wegovy
Fierce Pharma
Eli Lilly
clinical trials
obesity
Mounjaro
Novo Nordisk
Wegovy
Flag link:
Finding the big spenders beyond big pharma
Finding the big spenders beyond big pharma
EP Vantage
R&D
Amgen
Bayer
Biogen
Gilead Sciences
Merck KGaA
Moderna Therapeutics
Novo Nordisk
Regeneron Pharmaceuticals
UCB
Vertex Pharmaceuticals
Flag link:
What spurred Lilly, Novo and Sanofi to slash insulin prices? Expert gives her take
What spurred Lilly, Novo and Sanofi to slash insulin prices? Expert gives her take
Fierce Pharma
Novo Nordisk
Eli Lilly
Sanofi
insulin
diabetes
drug prices
Flag link:
Big pharma holds steady on research spending
Big pharma holds steady on research spending
EP Vantage
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Flag link:
With Wegovy supply unfettered, Novo Nordisk ratchets up its 2023 growth forecast
With Wegovy supply unfettered, Novo Nordisk ratchets up its 2023 growth forecast
Fierce Pharma
Novo Nordisk
Wegovy
Flag link:
Novo’s latest deal targets cell therapy for diabetes, obesity
Novo’s latest deal targets cell therapy for diabetes, obesity
BioPharma Dive
Novo Nordisk
cell therapy
diabetes
obesity
Aspect Biosystems
Flag link:

Pages